Ixekizumab

• Used for moderate to severe plaque psoriasis
• Anti-IL-17A monoclonal antibody

Adverse Events

• Common: neutropenia, hypersensitivity reactions, infections including pneumonia, injection site reactions
• Uncommon: superficial fungal infections, nausea, thrombocytopenia, antibody development
• Rare: Crohn disease and ulcerative colitis (including causing exacerbations), oral candidiasis, influenza, conjunctivitis, and rhinitis